TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by RiverPark Advisors LLC

by · The Cerbat Gem

RiverPark Advisors LLC lowered its stake in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 17.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,697 shares of the company’s stock after selling 765 shares during the quarter. RiverPark Advisors LLC’s holdings in TransMedics Group were worth $580,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new position in TransMedics Group in the 2nd quarter worth about $47,000. USA Financial Formulas purchased a new position in TransMedics Group in the 3rd quarter worth about $55,000. J.Safra Asset Management Corp increased its stake in TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after purchasing an additional 383 shares in the last quarter. Signaturefd LLC increased its stake in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

TMDX has been the subject of a number of research reports. Oppenheimer decreased their price objective on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. JPMorgan Chase & Co. decreased their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th. Needham & Company LLC decreased their price objective on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of TransMedics Group in a research report on Tuesday, October 29th. Finally, Robert W. Baird decreased their price objective on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $144.80.

Get Our Latest Stock Report on TMDX

TransMedics Group Stock Down 8.9 %

Shares of TMDX stock opened at $80.48 on Friday. The stock’s 50 day simple moving average is $125.63 and its 200 day simple moving average is $139.40. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a twelve month low of $63.85 and a twelve month high of $177.37. The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of 85.62 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) earnings per share. As a group, research analysts predict that TransMedics Group, Inc. will post 1.07 EPS for the current year.

Insiders Place Their Bets

In other news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now owns 21,105 shares in the company, valued at approximately $3,714,902.10. This represents a 32.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,958 shares of company stock valued at $5,230,528 in the last three months. Company insiders own 7.00% of the company’s stock.

About TransMedics Group

(Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Articles

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).